Neurovascular pharmacology of migraine

European Journal of Pharmacology

Volumn 585, Issue 2-3, 2008, Pages 313-319

  MaassenVanDenBrink, Antoinette ^a   Chan, Kayi Y ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Arteriovenous anastomoses; CGRP; Closed cranial window; Human coronary artery; Human middle meningeal artery; Migraine; Triptans

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; ALMOTRIPTAN; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; DONITRIPTAN; ELETRIPTAN; ERGOTAMINE; ESTRADIOL; FROVATRIPTAN; ION CHANNEL; NEUROPEPTIDE; OLCEGEPANT; PHENYLEPHRINE; PROGESTERONE; RIZATRIPTAN; SEX HORMONE; SUBSTANCE P; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ARTERIOVENOUS FISTULA; BLOOD VESSEL; CAROTID ARTERY; CHEST TIGHTNESS; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG INHIBITION; DRUG MECHANISM; GENE MUTATION; HUMAN; ISOLATION PROCEDURE; MEDICAL RESEARCH; MICROSCOPY; MIGRAINE; NERVE FIBER; NERVE STIMULATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SENSORY NERVE; THORAX PAIN; TRIGEMINAL NERVE; VASODILATATION;

ANIMALS; ARTERIOVENOUS ANASTOMOSIS; BLOOD VESSELS; CEREBROVASCULAR DISORDERS; GONADAL STEROID HORMONES; HUMANS; MICE; MIGRAINE DISORDERS; RATS; SWINE;

EID: 43049112068     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.091     Document Type: Review

References (80)

1. Akerman S., Kaube H., and Goadsby P.J. Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br. J. Pharmacol. 140 (2003) 718-724
2. Arulmani U., Gupta S., MaassenVanDenBrink A., Centurión D., Villalón C.M., and Saxena P.R. Experimental migraine models and their relevance in migraine therapy. Cephalalgia 26 (2006) 642-659
3. Bertrand M.E., LaBlanche J.M., Tilmant P.Y., Thieuleux F.A., Delforge M.R., Carre A.G., Asseman P., Berzin B., Libersa C., and Laurent J.M. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation 65 (1982) 1299-1306
4. Bott-Silverman C., and Heupler Jr. F.A. Natural history of pure coronary artery spasm in patients treated medically. J. Am. Coll. Cardiol. 2 (1983) 200-205
5. Bou J., Gras J., Cortijo J., Morcillo E.J., Llenas J., and Palacios J.M. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 21 (2001) 804-812
6. Brown E.G., Endersby C.A., Smith R.N., and Talbot J.C. The safety and tolerability of sumatriptan: an overview. Eur. Neurol. 31 (1991) 339-344
7. Chai W., Mehrotra S., Jan Danser A.H., and Schoemaker R.G. The role of calcitonin gene-related peptide (CGRP) in ischemic preconditioning in isolated rat hearts. Eur. J. Pharmacol. 531 (2006) 246-253
8. Comer M.B. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache 42 Suppl 2 (2002) S47-S53
9. + pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat. Genet. 33 (2003) 192-196
10. De Vries P., Heiligers J.P.C., Villalón C.M., and Saxena P.R. Blockade of porcine carotid vascular response to sumatriptan by GR 127935, a selective 5-HT1D receptor antagonist. Br. J. Pharmacol. 118 (1996) 85-92
11. De Vries P., Villalón C.M., Heiligers J.P.C., and Saxena P.R. Characterization of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors. Br. J. Pharmacol. 123 (1998) 1561-1570
12. De Vries P., Villalón C.M., and Saxena P.R. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur. J. Pharmacol. 375 (1999) 61-74
13. Den Boer M.O., Van Woerkens L.J., Somers J.A., Duncker D.J., Lachmann B., Saxena P.R., and Verdouw P.D. On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J. Appl. Physiol. 75 (1993) 782-789
14. Dichgans M., Freilinger T., Eckstein G., Babini E., Lorenz-Depiereux B., Biskup S., Ferrari M.D., Herzog J., van den Maagdenberg A.M., Pusch M., and Strom T.M. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366 (2005) 371-377
15. Dodick D., Lipton R.B., Martin V., Papademetriou V., Rosamund W., MaassenVanDenBrink A., Loutfi H., Welch K.M.A., Goadsby P.J., Hahn S., Hutchinson S., Matchar D., Silberstein S.D., Smith T.R., Purdy R.A., and Saiers J. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44 (2004) 414-425
16. Dong Y.L., Fang L., Kondapaka S., Gangula P.R., Wimalawansa S.J., and Yallampalli C. Involvement of calcitonin gene-related peptide in the modulation of human myometrial contractility during pregnancy. J. Clin. Invest. 104 (1999) 559-565
17. Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., and Eberlein W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129 (2000) 420-423
18. Drummond P.D., and Lance J.W. Extracranial vascular changes and the source of pain in migraine headache. Ann. Neurol. 13 (1983) 32-37
19. Drummond P.D., and Lance J.W. Facial temperature in migraine, tension-vascular and tension headache. Cephalalgia 4 (1984) 149-158
20. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 24 (2004) 611-622
21. Edvinsson L., Alm R., Shaw D., Rutledge R.Z., Koblan K.S., Longmore J., and Kane S.A. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. J. Pharmacol. 434 (2002) 49-53
22. Facchinetti F., Nappi R.E., Tirelli A., Polatti F., Nappi G., and Sances G. Hormone supplementation differently affects migraine in postmenopausal women. Headache 42 (2002) 924-929
23. Fusco M., D'Andrea G., Micciche F., Stecca A., Bernardini D., and Cananzi A.L. Neurogenic inflammation in primary headaches. Neurol. Sci. 24 Suppl 2 (2003) S61-S64
24. Gangula P.R., Zhao H., Wimalawansa S.J., Supowit S.C., DiPette D.J., and Yallampalli C. Pregnancy and steroid hormones enhance the systemic and regional hemodynamic effects of calcitonin gene-related peptide in rats. Biol. Reprod. 64 (2001) 1776-1783
25. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine - current understanding and treatment. N. Engl. J. Med. 346 (2002) 257-270
26. Gulbenkian S., Cuhmna e Sa M., Pinto Barosso C., and Edvinsson L. Innervation of intracranial blood vessels (1999), Martin Dunitz Ltd., Londen
27. Gupta S., Akerman S., van den Maagdenberg A.M.J.M., Saxena P.R., Goadsby P.J., and MaassenVanDenBrink A. Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine. Cephalalgia 26 (2006) 1294-1303
28. Gupta S., Mehrotra S., Avezaat C.J.J., Villalón C.M., Saxena P.R., and MaassenVanDenBrink A. Characterisation of CGRP receptors in the human isolated middle meningeal artery. Life Sci. 79 (2006) 265-271
29. Gupta S., Mehrotra S., Villalón C.M., Garrelds I.M., de Vries R., van Kats J.P., Sharma H.S., Saxena P.R., and MaassenVanDenBrink A. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur. J. Pharmacol. 530 (2006) 107-116
30. Gupta S., Lozano-Cuenca J., Villalón C.M., de Vries R., Garrelds I.M., Avezaat C.J.J., van Kats J.P., Saxena P.R., and MaassenVanDenBrink A. Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries. Naunyn Schmiedeberg's Arch. Pharmacol. 375 (2007) 29-38
31. Gupta S., Mehrotra S., Villalón C.M., Perusquía M., Saxena P.R., and MaassenVanDenBrink A. Potential role of female sex hormones in the pathophysiology of migraine. Pharmacology and Therapeutics 113 (2007) 321-340
32. Gupta S., Villalón C.M., Mehrotra S., de Vries R., Garrelds I.M., Saxena P.R., and MaassenVanDenBrink A. Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin. Headache 47 (2007) 225-235
33. Hales J.R.S. Radioactive microsphere techniques for studies of circulation. Clin. Exp. Pharmacol. Physiol. 75 (1974) 782-789
34. Heyck H. Pathogenesis of migraine. Research clinical study. Headache 2 (1969) 1-28
35. Humphrey P.P.A., and Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci. 12 (1991) 444-446
36. Jansen I., Alafaci C., Uddman R., and Edvinsson L. Evidence that calcitonin gene-related peptide contributes to the capsaicin-induced relaxation of guinea pig cerebral arteries. Regul. Pept. 31 (1990) 167-178
37. Jansen-Olesen I., Jorgensen L., Engel U., and Edvinsson L. In-depth characterization of CGRP receptors in human intracranial arteries. Eur. J. Pharmacol. 481 (2003) 207-216
38. Kalsner S. The coronary artery. In: Kalsner S. (Ed). The coronary artery (1982), Croom Helm, Londen 551
39. Kapoor K., Arulmani U., Heiligers J.P.C., Garrelds I.M., Willems E.W., Doods H., Villalón C.M., and Saxena P.R. Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Br. J. Pharmacol. 140 (2003) 329-338
40. Lipton R.B., Stewart W.F., Diamond S., Diamond M.L., and Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41 (2001) 646-657
41. Longmore J., Razzaque Z., Shaw D., Davenport A.P., Maguire J., Pickard J.D., Schofield W.N., and Hill R.G. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br. J. Clin. Pharmacol. 46 (1998) 577-582
42. Longmore J., Shaw D., Smith D., Hopkins R., McAllister G., Pickard J.D., Sirinathsinghji D.J., Butler A.J., and Hill R.G. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 17 (1997) 833-842
43. Ma Q.L., Zhou H.Y., and Sun M. [Relationship between sex hormone levels and blood calcitonin gene-related peptide/endothelin-1 in postmenopausal women with coronary heart disease]. Hunan Yi Ke Da Xue Xue Bao 26 (2001) 146-148
44. MaassenVanDenBrink A., and Saxena P.R. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache 44 Suppl 1 (2004) S13-S19
45. MaassenVanDenBrink A., van den Broek R.W.M., de Vries R., Bogers A.J.J.C., Avezaat C.J.J., and Saxena P.R. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55 (2000) 1524-1530
46. MacAlpin R.N. Correlation of the location of coronary arterial spasm with the lead distribution of ST segment elevation during variant angina. Am. Heart J. 99 (1980) 555-564
47. MacGregor E.A., and Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 63 (2004) 351-353
48. Nappi R.E., Cagnacci A., Granella F., Piccinini F., Polatti F., and Facchinetti F. Course of primary headaches during hormone replacement therapy. Maturitas 38 (2001) 157-163
49. 2+ channel gene CACNL1A4. Cell 87 (1996) 543-552
50. O'Shaughnessy C.T., Waldron G.J., and Connor H.E. Lack of effect of sumatriptan and UK-14,304 on capsaicin-induced relaxation of guinea-pig isolated basilar artery. Br. J. Pharmacol. 108 (1993) 191-195
51. Petersen K.A., Birk S., Doods H., Edvinsson L., and Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br. J. Pharmacol. 143 (2004) 697-704
52. Razzaque Z., Heald M.A., Pickard J.D., Maskell L., Beer M.S., Hill R.G., and Longmore J. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br. J. Clin. Pharmacol. 47 (1999) 75-82
53. Sams-Nielsen A., Orskov C., and Jansen-Olesen I. Pharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminals. Br. J. Pharmacol. 132 (2001) 1145-1153
54. Sang C.N., Ramadan N.M., Wallihan R.G., Chappell A.S., Freitag F.G., Smith T.R., Silberstein S.D., Johnson K.W., Phebus L.A., Bleakman D., Ornstein P.L., Arnold B., Tepper S.J., and Vandenhende F. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24 (2004) 596-602
55. Saxena P.R. Cranial arteriovenous shunting, an in vivo animal model for migraine. In: Olesen J., and Moskowitz M.A. (Eds). Experimental headache models (1995), Lippincott-Raven Publishers, Philadelphia, USA 189-198
56. Saxena P.R., and Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraines. In: Olesen J., Goadsby P.J., Ramadan N.M., Tfelt-Hansen P., and Welch K.M.A. (Eds). The Headaches (2006), Lippincott Williams & Wilkins, Philadelphia
57. Saxena P.R., and Tfelt-Hansen P. Sumatriptan. In: Olesen J., Ramadan N.M., Tfelt-Hansen P., and Welch K.M.A. (Eds). The Headaches (1993), Raven Press Ltd., New York 329-341
58. Saxena P.R., and Tfelt-Hansen P. Triptans, 5-HT1b/1d receptor agonists in acute treatment of migraine. In: Olesen J., Goadsby P.J., Ramadan N., Tfelt-Hansen P., and Welch K.M.A. (Eds). The Headache (2005), Lippincott Williams&Wilkins, Philadelphia, USA 469-503
59. Schmuck K., Ullmer C., Kalkman H.O., Probst A., and Lubbert H. Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache?. Eur. J. Neurosci. 8 (1996) 959-967
60. Shepherd S.L., Williamson D.J., Beer M.S., Hill R.G., and Hargreaves R.J. Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36 (1997) 525-533
61. Silberstein S.D. Headaches in pregnancy. Neurol. Clin. 22 (2004) 727-756
62. Silberstein S.D. Migraine pathophysiology and its clinical implications. Cephalalgia 24 Suppl 2 (2004) 2-7
63. Stewart W.F., Linet M.S., Celentano D.D., Van Natta M., and Ziegler D. Age- and sex-specific incidence rates of migraine with and without visual aura. Am. J. Epidemiol. 134 (1991) 1111-1120
64. Stewart W.F., Lipton R.B., Celentano D.D., and Reed M.L. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. J.A.M.A. 267 (1992) 64-69
65. Szallasi A., and Blumberg P.M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol. Rev. 51 (1999) 159-212
66. Tfelt-Hansen P., De Vries P., and Saxena P.R. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60 (2000) 1259-1287
67. Tom B., De Vries P., Heiligers J.P.C., Willems E.W., Kapoor K., John G.W., and Saxena P.R. Effects of donitriptan on carotid haemodynamics and cardiac output distribution in anaesthetized pigs. Cephalalgia 22 (2002) 37-47
68. Totaro R., De Matteis G., Marini C., Baldassarre M., and Carolei A. Sumatriptan and cerebral blood flow velocity changes during migraine attacks. Headache 37 (1997) 635-639
69. van den Broek R.W.M., MaassenVanDenBrink A., de Vries R., Bogers A.J.J.C., Stegmann A.P., Avezaat C.J.J., and Saxena P.R. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur. J. Pharmacol. 407 (2000) 165-173
70. van den Broek R.W.M., MaassenVanDenBrink A., Mulder P.G., Bogers A.J.J.C., Avezaat C.J.J., John G.W., and Saxena P.R. Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries. Eur. J. Pharmacol. 443 (2002) 125-132
71. van den Maagdenberg A.M.J.M., Pietrobon D., Pizzorusso T., Kaja S., Broos L.A., Cesetti T., van de Ven R.C., Tottene A., van der Kaa J., Plomp J.J., Frants R.R., and Ferrari M.D. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 41 (2004) 701-710
72. Verheggen R., Hundeshagen A.G., Brown A.M., Schindler M., and Kaumann A.J. 5-HT1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol. 124 (1998) 1345-1354
73. Villalón C.M., Centurión D., Valdivia L.F., De Vries P., and Saxena P.R. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc. West. Pharmacol. Soc. 45 (2002) 199-210
74. Visser W.H., Jaspers N.M., de Vriend R.H., and Ferrari M.D. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 16 (1996) 554-559
75. Wang S.J., Fuh J.L., Lu S.R., Juang K.D., and Wang P.H. Migraine prevalence during menopausal transition. Headache 43 (2003) 470-478
76. Willems E.W., De Vries P., Heiligers J.P.C., and Saxena P.R. Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedeberg's Arch. Pharmacol. 358 (1998) 212-219
77. Willems E.W., Trion M., De Vries P., Heiligers J.P.C., Villalón C.M., and Saxena P.R. Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br. J. Pharmacol. 127 (1999) 1263-1271
78. Williamson D.J., and Hargreaves R.J. Neurogenic inflammation in the context of migraine. Microsc. Res. Tech. 53 (2001) 167-178
79. Williamson D.J., Hargreaves R.J., Hill R.G., and Shepheard S.L. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 17 (1997) 518-524
80. Williamson D.J., Hargreaves R.J., Hill R.G., and Shepheard S.L. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 17 (1997) 525-531